Journal of Clinical Oncology

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation

PURPOSE The likelihood of finding a human leukocyte antigen (HLA)–matched unrelated donor (MUD) for hematopoietic cell transplantation can be predicted using a donor search prognos...

Reply to: “Beyond 1 Month: A Broader Look at the ROBOMET Trial Results” and “ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?”

Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer

Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus Perdere

Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates

Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality

PURPOSE Use of cytotoxic chemotherapy at end-of-life (EOL) is associated with adverse quality of life, increased health care utilization, and lower hospice rates. Although EOL cyto...

Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AML

PURPOSE Ziftomenib—a potent, highly selective, oral menin inhibitor—was well tolerated and demonstrated encouraging clinical activity as monotherapy for rela...

PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer

PURPOSE To assess modified folinic acid/leucovorin, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX [mFFX]) versus gemcitabine/nab-paclitaxel (GnP) in de novo metastatic pancreat...

Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report

PURPOSE Among childhood cancer survivors, we evaluated not previously explored relationships between colorectal subsequent malignant neoplasm (SMN) incidence and colorectum-specifi...

Erratum: Phase II Study of ¹⁷⁷ Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers

Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial

ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?

Bridging the Gap: Molecular Profiling to Guide Treatment Selection in Metastatic Pancreatic Cancer

Personalizing Chemotherapy in Metastatic Pancreatic Cancer

Beyond 1 Month: A Broader Look at the ROBOMET Trial Results

Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial

PURPOSE Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) and nab-paclitaxel + gemcitabine are recommended as first-line treatments for metastatic pancre...